All In Biotech

BLA 022458 · Pfizer

Elelyso

Taliglucerase Alfa · Intravenous · Hydrolytic Lysosomal Glucocerebroside-specific Enzyme

NovelOrphan

Last checked: Nov 20, 2026Latest source record: Dec 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2012

May 1, 2012

Approved uses

4

Original approval plus efficacy supplements

Registered trials

11

6 Phase 3, 0 recruiting

FAERS reports

576

418 serious, 49 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS Patients treated with enzyme replacement therapies have experienced life‑threatening hypersensitivity reactions, including anaphylaxis. Anaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy. Initiate ELELYSO in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue ELELYSO and immediately initiate appropriate medical treatment, including use of epinephrine. Inform patients of the symptoms of life‑threatening hypersensitivity reactions, including anaphylaxis and to seek immediate medical care should symptoms occur [see Warnings and Precautions (5.1) ] . WARNING: HYPERSENSITIVITY REACTIONS INCLUDING...

What it is approved for

From the label in effect Dec 29, 2025.

ELELYSO is indicated for the treatment of patients 4 years of age and older with a confirmed diagnosis of Type 1 Gaucher disease. ELELYSO is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for the treatment of patients 4 years and older with a confirmed diagnosis of Type 1 Gaucher disease ( 1 ).

Mechanism: Gaucher disease is an autosomal recessive disorder caused by mutations in the human glucocerebrosidase gene, which results in a reduced activity of the lysosomal enzyme glucocerebrosidase. Glucocerebrosidase catalyzes the conversion of the sphingolipid glucocerebroside into glucose and ceramide. The enzymatic deficiency results in accumulation of substrate glucocerebroside primarily in the lysosomal compartment of macrophages, giving rise to foam cells or "Gaucher cells," which accumulate in the liver, spleen and bone marrow. ELELYSO, an enzyme replacement therapy, is a recombinant analog of...

Therapeutic areas: Rare and genetic disease

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 20, 2016 Supplement 13 · Efficacy OrphanLetterLabel
  • Nov 20, 2015 Supplement 7 · Efficacy LabelLetter
  • Aug 27, 2014 Supplement 3 · Efficacy OrphanLetterLabel
  • May 1, 2012 Original approval · Type 1 - New Molecular Entity NovelOrphanReviewLetterLabel
1 products under this application
  • ELELYSO · TALIGLUCERASE ALFA 200 UNITS/VIAL · POWDER, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Taliglucerase Alfa" as an intervention, any sponsor and status, largest first.

All 11 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue71
  • arthralgia47
  • headache47
  • off label use47
  • malaise46
  • pain46
  • pyrexia46
  • pain in extremity45
  • dyspnoea40
  • inappropriate schedule of product administration38
  • nausea38
  • back pain36

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20081
20112
201212
201337
201425
201529
201646
201760
201857
201938
202049
202124
202240
202330
202439
202555
202632

Recalls

2 FDA enforcement reports for this application.

  • Feb 27, 2020 · Class II · Terminated

    Lack of Assurance of Sterility--Reports of loose metal ferrule crimps on vials for injection. The entire cap either lifted or dislodged while attempting to flip off the orange color plastic button.

  • Sep 19, 2018 · Class II · Terminated

    Lack of assurance of sterility -Reports of loose metal ferrule crimps on vials for injection. The entire cap either lifted or dislodged while attempting to flip off the orange color plastic button.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Elelyso (Taliglucerase Alfa)

2024 spending

$2.8M

Beneficiaries

n/a

62 claims

Per beneficiary

n/a

$873.09 per unit

View as table
YearSpending
2020$3,027,301
2021$3,135,062
2022$3,677,950
2023$2,779,778
2024$2,786,025

Part B: Elelyso (Taliglucerase Alfa) · HCPCS J3060

2024 spending

$5.0M

Beneficiaries

12

185 claims

Per beneficiary

$419,589

2024 ASP limit $44.30 per unit

View as table
YearSpending
2020$4,825,582
2021$4,479,298
2022$4,550,835
2023$5,093,939
2024$5,035,065

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 11 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.